Atrium Therapeutics Inc (RNA)

Currency in USD
13.65
+0.35(+2.63%)
Closed·
13.650.00(0.00%)
·
RNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.2013.72
52 wk Range
11.4016.77
Key Statistics
Prev. Close
13.3
Open
13.4
Day's Range
13.2-13.72
52 wk Range
11.4-16.77
Volume
196.85K
Average Volume (3m)
297.6K
1-Year Change
-
Book Value / Share
15.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.00
Upside
+83.15%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Atrium Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.00
(+83.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.97 / --
Revenue / Forecast
19.64M / --
EPS Revisions
Last 90 days

RNA Income Statement

Compare RNA to Peers and Sector

Metrics to compare
RNA
Peers
Sector
Relationship
P/E Ratio
−4.0x−2.5x−0.4x
PEG Ratio
-−0.150.00
Price/Book
1.0x2.0x2.6x
Price / LTM Sales
6.4x4.3x3.0x
Upside (Analyst Target)
83.2%21.4%49.1%
Fair Value Upside
Unlock27.7%6.1%Unlock

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.25M24.85%58.03M
Other Institutional Investors
11.51M67.31%157.16M
Public Companies & Retail Investors
1.34M7.84%18.30M
Total
17.11M100.00%233.49M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.9.08%1,553,21021,201
BlackRock, Inc.7.05%1,205,29116,452

People Also Watch

17.49
AERO
-0.68%
26.50
ALMS
-0.53%
20.445
ENI
+0.17%
48.09
AMWD
+12.97%
58.39
PCVX
+4.12%

FAQ

What Is the Atrium Therapeutics (RNA) Stock Price Today?

The Atrium Therapeutics stock price today is 13.65 USD.

What Stock Exchange Does Atrium Therapeutics Trade On?

Atrium Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Atrium Therapeutics?

The stock symbol for Atrium Therapeutics is "RNA."

What Is the Atrium Therapeutics Market Cap?

As of today, Atrium Therapeutics market cap is 233.49M USD.

What Is Atrium Therapeutics's Earnings Per Share (TTM)?

The Atrium Therapeutics EPS (TTM) is -3.43.

When Is the Next Atrium Therapeutics Earnings Date?

Atrium Therapeutics will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is RNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Atrium Therapeutics Stock Split?

Atrium Therapeutics has split 0 times.

What is the current trading status of Atrium Therapeutics (RNA)?

As of Jul 04, 2026, Atrium Therapeutics (RNA) is trading at a price of 13.65 USD, with a previous close of 13.30 USD. The stock has fluctuated within a day range of 13.20 USD to 13.72 USD, while its 52-week range spans from 11.40 USD to 16.77 USD.

What Is Atrium Therapeutics (RNA) Price Target According to Analysts?

The average 12-month price target for Atrium Therapeutics is 25.00 USD, with a high estimate of 25 USD and a low estimate of 25 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +83.15% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.